{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:53:46Z","timestamp":1772006026964,"version":"3.50.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1097\/ftd.0b013e31825c4bc3","type":"journal-article","created":{"date-parts":[[2012,6,13]],"date-time":"2012-06-13T07:06:33Z","timestamp":1339571193000},"page":"446-451","source":"Crossref","is-referenced-by-count":28,"title":["Isoniazid Pharmacokinetics, Pharmacodynamics, and Dosing in South African Infants"],"prefix":"10.1097","volume":"34","author":[{"given":"Jennifer J.","family":"Kiser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Z.","family":"D'Argenio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark F.","family":"Cotton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raziya","family":"Bobat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George D.","family":"McSherry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shabir A.","family":"Madhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent J.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiner I.","family":"Seifart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cedric J.","family":"Werely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney V.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"suppl 3","key":"R1-13-20210129","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1086\/651490","article-title":"Pediatric tuberculosis: global overview and challenges.","volume":"50","author":"Swaminathan","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R2-13-20210129","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2165\/00003088-197904060-00001","article-title":"Clinical pharmacokinetics of isoniazid.","volume":"4","author":"Weber","year":"1979","journal-title":"Clin Pharmacokinet"},{"key":"R3-13-20210129","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1080\/10937400903158383","article-title":". Genetic polymorphism in N-acetyltransferase (NAT): population distribution of NAT1 and NAT2 activity.","volume":"12","author":"Walker","year":"2009","journal-title":"J Toxicol Environ Health"},{"key":"R4-13-20210129","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2174\/138920007782798216","article-title":"Isoniazid: metabolic aspects and toxicological correlates.","volume":"8","author":"Preziosi","year":"2007","journal-title":"Curr Drug Metab"},{"key":"R5-13-20210129","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1086\/424999","article-title":". The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid.","volume":"39","author":"Donald","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R6-13-20210129","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1011214","article-title":". Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children.","volume":"365","author":"Madhi","year":"2011","journal-title":"N Engl J Med"},{"key":"R7-13-20210129","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0378-4347(96)82886-6","article-title":". High-performance liquid chromatographic determination of isoniazid, acetylisoniazid and hydrazine in biological fluids.","volume":"674","author":"Seifart","year":"1995","journal-title":"J Chromatogr"},{"key":"R8-13-20210129","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/adc.2004.052175","article-title":". Isoniazid pharmacokinetics in children treated for respiratory tuberculosis.","volume":"90","author":"Schaaf","year":"2005","journal-title":"Arch Dis Child"},{"key":"R9-13-20210129","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/0091270011402826","article-title":". The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid.","volume":"52","author":"Zhu","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"R11-13-20210129","first-page":"1","article-title":"The R Package geepack for generalized estimating equations.","volume":"15","author":"Hojsgaard","year":"2005","journal-title":"J Stat Software"},{"key":"R13-13-20210129","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2165\/00003495-200262150-00001","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis.","volume":"62","author":"Peloquin","year":"2002","journal-title":"Drugs"},{"key":"R14-13-20210129","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1086\/599040","article-title":". Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.","volume":"48","author":"Chideya","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R15-13-20210129","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1086\/598192","article-title":". Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines.","volume":"48","author":"McIlleron","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R16-13-20210129","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00228-007-0305-5","article-title":". The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.","volume":"63","author":"Donald","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"R17-13-20210129","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2125.2011.03940.x","article-title":". Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients.","volume":"72","author":"Wilkins","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"R19-13-20210129","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1164\/ajrccm.155.5.9154882","article-title":". Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis.","volume":"155","author":"Parkin","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"R20-13-20210129","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF00541539","article-title":"Pharmacokinetics of isoniazid: influence of age.","volume":"30","author":"Kergueris","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"R21-13-20210129","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1472-8206.2001.00044.x","article-title":". Isoniazid pharmacokinetics in children according to acetylator phenotype.","volume":"15","author":"Rey","year":"2001","journal-title":"Fundam Clin Pharmacol"},{"key":"R22-13-20210129","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/bmj.39000.486400.55","article-title":". Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.","volume":"334","author":"Zar","year":"2007","journal-title":"BMJ"},{"key":"R23-13-20210129","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":". Developmental pharmacologydrug disposition, action, and therapy in infants and children.","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e31825c4bc3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:39:46Z","timestamp":1620952786000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201208000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e31825c4bc3","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}